Effect of Recombinant Human Growth Hormone (rhGH) Use on Genetic Methylation Patterns and Their Relationship with Body Composition in Small-for-Gestational-Age (SGA) Newborns

<b>Background:</b> Low birth weight in newborns is of multifactorial origin (fetal, maternal, placental, and environmental factors), and in one-third of cases, the cause is of unknown origin, with high infant morbidity and mortality. The main treatment for regaining weight and height in children with low birth weight is the application of growth hormones. However, their role as a protective factor to prevent an increase in body composition and the development of metabolic diseases is still poorly understood. <b>Methodology</b>: A case-control study was conducted in a cohort of patients consulted at the CES Pediatric Endocrinology Clinic, Medellín, Colombia, between 2008 and 2018. We evaluated sociodemographic and clinical variables. Additionally, the identification of differential patterns of genomic methylation between cases (treated with growth hormone) and controls (without growth hormone treatment) was performed. The groups were compared using Fisher's exact test for qualitative variables and Student's <i>t</i>-test for the difference in means in independent samples. The correlation was evaluated with the Pearson coefficient. <b>Results:</b> Regarding clinical manifestations, body mass index (BMI) was higher in children who did not receive growth hormone treatment, higher doses of growth hormone treatment helped reduce body mass index (R: -0.21, and <i>p</i> = 0.067), and the use of growth hormone was related to a decrease in triglyceride blood concentrations (<i>p</i> = 0.06); these results tended towards significance. Regarding genome-wide methylation patterns, the following genes were found to be hypermethylated: <i>MDGA1, HOXA5, LINC01168, ZFYVE19, ASAH1, MYH15, DNAJC17, PAMR1, MROCKI, CNDP2, CBY2, ZADH2, HOOK2, C9orf129, NXPH2, OSCP1, ZMIZ2, RUNX1, PTPRS, TEX26, EIF2A4K, MYO1F, C2orf69</i>, and <i>ZSCAN1</i>. Meanwhile, the following genes were found hypomethylated: <i>C10orf71-AS1, ZDHHC13, RPL17, EMC4, RPRD2, OBSCN-AS1, ZNF714, MUC4, SUGT1P4, TRIM38, C3, SPON1, NGF-AS1, CCSER2, P2RX2, LOC284379, GGTA1, NLRP5, OR51A4, HLA-H</i>, and <i>TTLL8</i>. <b>Conclusions:</b> Using growth hormone as a treatment in SGA newborns helps regain weight and height. Additionally, it could be a protective factor against the increase in adolescent body composition.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2025-05-23
DOI
https://doi.org/10.3390/biomedicines13061288
Citations
2
Primary Topic
Birth, Development, and Health
Type
article
Field-Weighted Citation Impact
6.99

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of Recombinant Human Growth Hormone (rhGH) Use on Genetic Methylation Patterns and Their Relationship with Body Composition in Small-for-Gestational-Age (SGA) Newborns

Fernando P. Monroy, Rodrigo Urrego, Ronald Guillermo Pelaez Sánchez, Hernando Alirio Palacio Mosquera et al.
2 citations
Biomedicines
Birth, Development, and Health
6.99
article

Effect of Recombinant Human Growth Hormone (rhGH) Use on Genetic Methylation Patterns and Their Relationship with Body Composition in Small-for-Gestational-Age (SGA) Newborns

Fernando P. Monroy, Rodrigo Urrego, Ronald Guillermo Pelaez Sánchez, Hernando Alirio Palacio Mosquera, María del Pilar Montilla Velásquez, Claudia Soto, Sara Vélez Gómez, Elsa María Vásquez Trespalacios, Jorge Emilio Salazar Flórez, María Fabiola Toro, Juan Manuel Alfaro Velásquez, J. Velez, Verónica Jaramillo Henríquez
article en
2 citations

Abstract

<b>Background:</b> Low birth weight in newborns is of multifactorial origin (fetal, maternal, placental, and environmental factors), and in one-third of cases, the cause is of unknown origin, with high infant morbidity and mortality. The main treatment for regaining weight and height in children with low birth weight is the application of growth hormones. However, their role as a protective factor to prevent an increase in body composition and the development of metabolic diseases is still poorly understood. <b>Methodology</b>: A case-control study was conducted in a cohort of patients consulted at the CES Pediatric Endocrinology Clinic, Medellín, Colombia, between 2008 and 2018. We evaluated sociodemographic and clinical variables. Additionally, the identification of differential patterns of genomic methylation between cases (treated with growth hormone) and controls (without growth hormone treatment) was performed. The groups were compared using Fisher's exact test for qualitative variables and Student's <i>t</i>-test for the difference in means in independent samples. The correlation was evaluated with the Pearson coefficient. <b>Results:</b> Regarding clinical manifestations, body mass index (BMI) was higher in children who did not receive growth hormone treatment, higher doses of growth hormone treatment helped reduce body mass index (R: -0.21, and <i>p</i> = 0.067), and the use of growth hormone was related to a decrease in triglyceride blood concentrations (<i>p</i> = 0.06); these results tended towards significance. Regarding genome-wide methylation patterns, the following genes were found to be hypermethylated: <i>MDGA1, HOXA5, LINC01168, ZFYVE19, ASAH1, MYH15, DNAJC17, PAMR1, MROCKI, CNDP2, CBY2, ZADH2, HOOK2, C9orf129, NXPH2, OSCP1, ZMIZ2, RUNX1, PTPRS, TEX26, EIF2A4K, MYO1F, C2orf69</i>, and <i>ZSCAN1</i>. Meanwhile, the following genes were found hypomethylated: <i>C10orf71-AS1, ZDHHC13, RPL17, EMC4, RPRD2, OBSCN-AS1, ZNF714, MUC4, SUGT1P4, TRIM38, C3, SPON1, NGF-AS1, CCSER2, P2RX2, LOC284379, GGTA1, NLRP5, OR51A4, HLA-H</i>, and <i>TTLL8</i>. <b>Conclusions:</b> Using growth hormone as a treatment in SGA newborns helps regain weight and height. Additionally, it could be a protective factor against the increase in adolescent body composition.

BiomedicinesVol. 13(6)
Saint Martin University (CO), Northern Arizona University (US), Universidad de Antioquia (CO), Antioquia Institute of Technology (CO), Universidad CES (CO), Clínica CES (CO)
Pfizer, Universidad CES
Openalex Percentile: Top 4%
Birth, Development, and Health
6.99
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.